[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Tata Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":551},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,20,0,[8,50,79,108,131,159,181,209,237,262,280,306,328,354,384,416,441,466,484,522],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":4},"100638415","phase-ii-single-arm-open-label-study-evaluating-the-feasibility-and-safety-of-photobiomodulation-as-an-adjunct-to-standard-supportive-care-for-chemotherapy-induced-oral-mucositis-in-pediatric-patients-with-hematolymphoid-malignancies-100638415",false,"NCT07605234","Phase II Single Arm Open Label Study Evaluating the Feasibility and Safety of Photobiomodulation as an Adjunct to Standard Supportive Care for Chemotherapy Induced Oral Mucositis in Pediatric Patients With Hematolymphoid Malignancies","Phase II Single Arm Study of Photobiomodulation as an Adjunct to Standard Supportive Care for Chemotherapy Induced Oral Mucositis in Pediatric Patients","BEAM","Inclusion Criteria:\n\n* Pediatric patients aged 3 to 14 years\n* Diagnosed with hematolymphoid malignancies\n* Currently receiving chemotherapy\n* Presence of chemotherapy induced oral mucositis of World Health Organization grade 2 or higher at screening\n* Written informed consent obtained from parent or legal guardian along with age appropriate assent from the participant\n\nExclusion Criteria:\n\n* Pre existing oral mucosal disease unrelated to chemotherapy\n* Known photosensitivity or use of photosensitising medications\n* Uncontrolled infection or active bleeding\n* Any medical or clinical condition interfering with protocol compliance","ALL","3 Years","14 Years",{"count":21,"type":22},46,"ESTIMATED","INTERVENTIONAL",[25],"NA","Chemotherapy induced oral mucositis is a common and debilitating complication in pediatric patients receiving chemotherapy for hematolymphoid malignancies. Oral mucositis can cause painful mouth ulcers, difficulty in eating and drinking, impaired nutrition, increased risk of infection, and significant discomfort. In severe cases, oral mucositis may lead to interruptions, delays, or dose modifications in chemotherapy, which can negatively affect cancer treatment outcomes and quality of life. Current management of chemotherapy induced oral mucositis is mainly supportive and includes maintenance of oral hygiene, bland mouth rinses, topical anesthetics, systemic analgesics, antimicrobial therapy when indicated, and nutritional support. However, these measures do not consistently promote healing of the oral mucosa or reduce the duration and severity of oral mucositis.\n\nPhotobiomodulation therapy is a non invasive treatment modality that uses low level red light to stimulate tissue repair, reduce inflammation, and improve pain control. Increasing evidence suggests that photobiomodulation therapy may reduce the severity and duration of chemotherapy induced oral mucositis and improve patient comfort. The treatment is painless, does not involve injections or additional medications, and has shown a favorable safety profile in previous studies. International supportive care guidelines have recommended photobiomodulation therapy in selected oncology settings for the management of oral mucositis.\n\nThe purpose of this Phase II single arm open label interventional study is to evaluate the feasibility and safety of photobiomodulation therapy as an adjunct to standard supportive care in pediatric patients with chemotherapy induced oral mucositis. The study will also explore preliminary clinical outcomes related to oral mucositis severity, pain control, nutritional support, and treatment interruptions.\n\nThis study will be conducted at Tata Memorial Hospital in Mumbai, India. Pediatric patients aged 3 to 14 years with hematolymphoid malignancies who are receiving chemotherapy and develop World Health Organization grade 2 or higher oral mucositis will be eligible for participation. Written informed consent will be obtained from parents or legal guardians along with age appropriate assent from the child before enrollment.\n\nParticipants enrolled in the study will continue to receive standard supportive care for oral mucositis as per institutional protocol. In addition, participants will receive photobiomodulation therapy administered using a handheld low level laser device operating at a wavelength of 660 nanometer. Photobiomodulation therapy will be administered once daily for four consecutive days by trained clinicians. The procedure is expected to take approximately 5 to 10 minutes depending on the extent of oral lesions.\n\nBaseline assessments will include demographic details, diagnosis, chemotherapy information, oral mucositis grading, pain assessment, nutritional status, and routine blood investigation results including absolute neutrophil count where available. Oral mucositis severity will be assessed using World Health Organization oral mucositis grading and National Cancer Institute Common Terminology Criteria for Adverse Events version 6 grading systems. Pain will be assessed using the visual analog scale.\n\nParticipants will undergo daily assessments during the intervention period. Researchers will record oral mucositis severity, pain scores, analgesic requirement, nutritional support requirement, chemotherapy delays or interruptions, and adverse events. Absolute neutrophil count values obtained as part of routine oncologic care will also be documented. No additional blood investigations will be performed specifically for study purposes.\n\nThe primary outcome of the study is feasibility, defined as the proportion of participants who complete the planned photobiomodulation therapy sessions. Secondary outcomes include improvement in oral mucositis severity by Day 7, change in oral mucositis grade over predefined time points, time to resolution of oral mucositis, change in pain scores, analgesic consumption, nutritional support requirement, chemotherapy delays or interruptions, trends in absolute neutrophil count, and safety and tolerability of photobiomodulation therapy.\n\nParticipants will be followed until Day 10 after initiation of therapy for final clinical assessment and documentation of any late adverse events. The study aims to generate preliminary data regarding the feasibility and safety of photobiomodulation therapy in pediatric oncology patients with chemotherapy induced oral mucositis. If found to be feasible and well tolerated, photobiomodulation therapy may become a practical and cost effective adjunctive supportive care option for children receiving chemotherapy.",[28,29],"Oral Mucositis Due to Chemotherapy","Hematolymphoid Malignancies",[31,32,33,34,35,29,36,37],"Photobiomodulation","Low Level Laser Therapy","Oral Mucositis","Chemotherapy","Pediatric Oncology","Supportive Care","mouth ulcers","NOT_YET_RECRUITING","2026-05-18",{"date":41,"type":42},"2026-05-22","ACTUAL",{"date":44,"type":22},"2026-06-01",{"date":46,"type":22},"2027-04-23",{"name":48,"class":49},"Tata Memorial Hospital","OTHER_GOV",{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":63,"conditions":64,"keywords":67,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},"100626437","late-radiation-toxicities-in-cervical-and-endometrial-cancer-a-postoperative-imrtbrachytherapy-study-100626437","NCT07435623","Late Radiation Toxicities in Cervical and Endometrial Cancer: A Postoperative IMRT\u002FBrachytherapy Study","Assessment of Late Gastrointestinal and Genitourinary Toxicities in Cervical and Endometrial Cancer Requiring Postoperative IMRT and\u002For Brachytherapy","Inclusion Criteria:\n\n* Patients more than 18 years of age at the time of diagnosis.\n* All patients with confirmed histological diagnosis of cervical or endometrial cancer.\n* Only those patients who have received adjuvant (chemo)radiotherapy with IMRT and\u002For brachytherapy at TMH\u002FACTREC will be included.\n* Patients whose follow up information available\n\nExclusion Criteria:\n\n* Patients with incomplete treatment details.\n* Patient having residual disease post-surgery.\n* Patient treated for post-operative recurrences.\n* Patient who lost to follow up.\n* Patients with Immunosuppressive disorder","FEMALE","18 Years","75 Years",{"count":61,"type":22},300,"OBSERVATIONAL","Cervical cancer is the 4th most common cancer in women globally and the 2nd most common in India. In India, between 2018 and 2020, cervical cancer saw a surge of 26,985 from 2018 to 2020. The treatment for cervical cancer depends on the clinical stage. Treatment of early stage cervical cancer (Stage IB1-IIA) includes chemo-radiation or surgery +\u002F- adjuvant (CT)RT and VBT if indicated. The choice of adjuvant treatment relies on identifying specific risk factors. Patients fulfilling Sedli's intermediate-risk criteria, requires pelvic radiotherapy alone and patients with high-risk Peter's criteria, require adjuvant chemoradiation. This risk-based approach helps tailor adjuvant therapies to individual patient.\n\nIndia reported 16,413 new cases and 6,385 deaths of endometrial cancer, with a mortality rate of 0.73%. The primary treatment for endometrial carcinoma is total abdominal hysterectomy with bilateral salpingo-oophorectomy (TAH-BSO). The Adjuvant treatment depends on risk stratification group according to ESGO\u002FESTRO\u002FESP guidelines determined through molecular-based risk stratification. Adjuvant treatment includes radiotherapy, chemotherapy, and brachytherapy.\n\nTo reduce the burden of acute and late toxicity, advanced external radiation techniques like image guided intensity modulated radiotherapy (IG IMRT) are used. IG IMRT have shown their potential to reduce late toxicity in long term survivors compared to 3DCRT technique. Since January 2020, our institution (TATA memorial centre, Mumbai) has incorporated routine IG-IMRT (Image-Guided Intensity-Modulated Radiation Therapy) for treatment of cervical and endometrial cancer. However, no post-implementation assessment of treatment outcomes and potential toxicity has occurred. This is retrospective observational study aims to evaluate the clinical application of IG-IMRT.\n\nPrimary aim of this study is to audit the 3 years incidence of ≥ grade II Gastrointestinal \\& Genitourinary toxicities in women receiving Adjuvant IMRT (with or without chemotherapy) between January 2020 to June 2023",[65,66],"Endometrial Cancer","Cervix Cancer",[68],"Cervical Cancer, Endometrical Cancer ,Gastrointestinal & Genitourinary toxicities","RECRUITING","2026-02-26",{"date":72,"type":42},"2026-03-02",{"date":74,"type":42},"2025-05-10",{"date":76,"type":22},"2026-08-25",{"name":48,"class":49},1,{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":86,"enrollmentInfo":87,"targetDuration":4,"studyType":23,"phases":88,"briefSummary":89,"conditions":90,"keywords":94,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":78},"100565643","spatially-fractionated-radiation-treatment-for-gynaecological-cancers-100565643","NCT06644846","Spatially Fractionated Radiation Treatment for Gynaecological Cancers","A Prospective Study of Spatially Fractionated Radiation Treatment Using Rapid Rod Technique for Gynaecological Cancers","Inclusion Criteria:\n\n1. Patients with cervical cancer post EBRT, with expected suboptimal brachytherapy dose coverage due to-\n\n   1. Aberrant uterine or pelvic anatomy leading to difficulty in localization of the cervical OS or negotiation of the uterine canal accurately by two independent clinicians in up to two procedures.\n   2. Large residual disease at the time of brachytherapy with anticipated suboptimal target coverage either determined in clinic based on pre-brachytherapy imaging or at dose planning (e.g. figure 2).\n   3. Very narrow vaginal canal not accommodating even the smallest intracavitary or vaginal cylinder applicators.\n2. Patients with inoperable endometrial cancer not suitable for anaesthesia or have anticipated suboptimal coverage of target volume at brachytherapy as identified on pre-brachytherapy imaging obtained after EBRT.\n3. Patients with large pelvic recurrences after surgery and\u002For (chemo) radiation, not amenable to surgical salvage or brachytherapy after salvage EBRT due to reasons specified in item 1.\n4. Patients with contraindications to anaesthesia for brachytherapy with sufficient risk of on-table or post procedure adverse events.\n\nExclusion Criteria:\n\n1. Any pre-existing fistula in bladder or rectum.\n2. Pelvic prosthesis.\n3. Refusal to provide consent.","70 Years",{"count":5,"type":22},[25],"This is a prospective study to evaluate in-field disease control, survival and late toxicity in patients with cervical cancer or pelvic recurrence treated with spatially fractionated RT.\n\nThe study will include patients with primary cervical cancer or pelvic recurrence not suitable for brachytherapy in view of anticipated or actual suboptimal target coverage due to aberrant anatomy or large residual disease at the time of brachytherapy.",[91,92,93],"Cervical Cancer","Gynecologic Cancer","Recurrent Cancer",[95,96,97,98,99],"Cervical cancer","Cancer","Recurrence","Spatially fractionated radiotherapy","Rapid rod","2026-02-18",{"date":102,"type":42},"2026-02-20",{"date":104,"type":42},"2024-10-04",{"date":106,"type":22},"2029-02-28",{"name":48,"class":49},{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":118,"conditions":119,"keywords":120,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":125,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":78},"100447115","development-of-clinically-high-efficient-platforms-for-individualised-treatment-of-cervix-cancer-100447115","NCT05102240","Development of Clinically High Efficient Platforms for Individualised Treatment of Cervix Cancer","Developing Clinical High Efficiency Platforms for Individualised Treatment Through Integration of Advanced Radiation Technology, Quantitative Imaging and Molecular Biology and Machine Learning for Treatment of Cervix Cancer.","Inclusion Criteria:\n\nFor Aim 1 and Aim 3:\n\n* Patients treated within ongoing and completed clinical trials of chemoradiation and brachytherapy for cervix cancer with access to MRI\u002FCT images at the time of diagnosis and brachytherapy For Aim 2\n* Patients undergoing postoperative or definitive radiotherapy and treated within trials of postoperative or definitive RT.\n\nExclusion Criteria:\n\n1. Lack of disease or toxicity outcomes.\n2. Lack of images in the hospital database.","90 Years",{"count":117,"type":22},1800,"Retrospective study utilizing patient data to develop and validate Machine Learning application. Available imaging data sets of patients who have completed treatment will be used to develop Normal tissue complication probability and Tumour control probability\n\nHypothesis Integrating existing radiation treatment information, quantitative imaging and patient outcome data from completed and ongoing clinical trials will allow development of knowledge based systems for efficient treatment delivery and allow selection of patients for intensified treatment approaches in cervix cancer.",[66],[121,122,123,124],"Advanced Radiation Technology","Quantitative Imaging","Molecular Biology","Machine Learning",{"date":102,"type":42},{"date":127,"type":42},"2022-02-24",{"date":129,"type":22},"2026-06-30",{"name":48,"class":49},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":137,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":139,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":141,"conditions":142,"keywords":148,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":152,"startDateStruct":154,"completionDateStruct":156,"leadSponsor":158,"locationsCount":78},"100623759","cervical-cancer-oligo-states-recurrence-metastasis-multicentre-outcomes-study-100623759","NCT07400809","Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retrospective Cervical Cancer Oligo States (Recurrence, Metastasis) Multicentre Outcomes Study.","Retro-COSMOS","Inclusion Criteria:\n\n1. Cervical cancer with (induced) oligo-metastatic and\u002For oligo-recurrent cervix cancer whether treated or not treated with radiation. These patients may have received previous treatment within or outside approved clinical trials\u002Fstudies.\n2. Patients with poly-metastatic disease with good response to systemic chemotherapy and treated with radiation to recurrence or metastatic site.\n3. Patients treated with radical doses at the time of first diagnosis of oligo-metastasis\u002Foligo-recurrence and present with further oligo-progression.\n4. Patients with oligo-metastasis or oligo-recurrence treated with other locally directed therapies (like surgery, ablation, etc.) are also permitted.\n\nExclusion Criteria:\n\n1. Gynaecological cancer other than cervical cancer.\n2. Persistent Poly-metastatic disease post systemic treatment\n3. Receiving investigational new drugs at the time of relapse as part of other ongoing trials.\n4. No clinical follow up after treatment",{"count":140,"type":22},350,"Systemic chemotherapy with or without palliative radiation represents the current standard of care in patients with recurrent or metastatic cervix cancer. In addition, pelvic radiotherapy including brachytherapy is also recommended. There is no consensus on the treatment of metastatic site in patients with oligo-metastatic or oligo-recurrent cervix cancer. Also, it is not clear if addition of local treatment to systemic chemotherapy benefits all patients with metastatic disease or a select few with limited systemic disease burden. It's presently unclear which patients derive maximum benefit with integration of radiation at both primary and metastatic site, who develop infield recurrence if performing salvage surgery, locally directed treatments or re-irradiation in addition to systemic chemotherapy improves overall outcomes. The heterogeneity in clinical practice provides an important opportunity to develop a framework for data collection and future studies within such subgroup of patients. In this retrospective study, we aim to determine overall survival, Infield progression free survival, overall progression free survival, dose response relationship of nodal and visceral progressions, and within setting of re-irradiation (infield progressions), severe adverse events and toxicity, risk groups identification, a nomogram which correlates risk groups with expected outcomes, and framework for tissue collection for translational research Investigators will record the parameters in a predesigned proforma without including personal identifiers.",[34,143,144,66,145,146,147],"Treatment Compliance","Radiotherapy","Surgery","Recurrent","Metastasis",[149,150],"Recurrent and Metastatic Cervix Cancer","Oligo States","2026-02-12",{"date":153,"type":42},"2026-02-17",{"date":155,"type":42},"2023-08-23",{"date":157,"type":22},"2027-06-14",{"name":48,"class":49},{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":164,"acronym":165,"eligibilityCriteria":166,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":170,"conditions":171,"keywords":172,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":151,"lastUpdatePostDateStruct":175,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":78},"100362278","palliative-radiation-for-advanced-cervical-cancer-100362278","NCT03997110","Palliative Radiation for Advanced Cervical Cancer","Rapid Palliation in Locally Advanced Cervical Cancer: A Phase III Randomized Trial","RAPPAL","Inclusion Criteria:\n\n1. Locally advanced cervical cancer (Stage IIIB-IVA) deemed unsuitable for full course radical pelvic radiotherapy or chemoradiation due to the following reasons:\n\n   * Very large volume hard fixed disease infiltrating pelvic wall muscles and ligaments on clinical examination also classified clinically as \"frozen pelvis\" wherein curative intent treatment is not envisaged or feasible.\n   * Fistulous communication between tumour growth and rectum and bladder \\>2x2 cm in size (as judged by cystoscopy for bladder infiltration or clinical or proctosigmoidoscopy examination for rectal\u002Fsigmoid infiltration) wherein radical intent treatment is not intended or feasible and patient is not a candidate for pelvic exenteration.\n   * Deranged renal parameters as measured by Serum Creatinine \\>3 mg\u002Fdl wherein diversion nephrostomy is not planned by the multidisciplinary team due to anticipated poor clinical outcomes.Furthermore concurrence for palliative intent radiotherapy should be corroborated by 2 staff radiation oncologists.\n2. Moderate to Severe Pain on Numerical Rating Score (Score 4 or higher).\n3. Anticipated survival \\\u003C 12 months.\n4. Patients with stage IVB with local disease extent as described in section 1 but systemic chemotherapy is not possible either due to deranged renal function or anticipated poor tolerance.\n\nExclusion Criteria:\n\n1. Patients with distant metastasis needing upfront systemic therapy.\n2. Presence of retroviral disease\n3. Non-compliant for follow up.\n4. Expected survival \\\u003C3 months.",{"count":168,"type":22},230,[25],"The present study is proposed to compare a rapid fractionation schedule of 1 week compared to a protracted schedule of 6-8 weeks for palliation for locally advanced cervical cancer.",[91],[91,173,174],"Palliative treatment","Radiation Therapy",{"date":153,"type":42},{"date":177,"type":42},"2020-06-19",{"date":179,"type":22},"2026-08-01",{"name":48,"class":49},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":186,"eligibilityCriteria":187,"healthyVolunteers":11,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":188,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":190,"conditions":191,"keywords":198,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":205,"leadSponsor":207,"locationsCount":208},"100608013","asian-gynecological-brachytherapy-registry-in-cervical-cancer-100608013","NCT07196033","Asian Gynecological Brachytherapy Registry in Cervical Cancer","AGBR-FERN-Gyn","Inclusion Criteria:\n\n* Patients diagnosed with FIGO 2018 stage IB-IVA cervical cancer with squamous cell carcinoma, adenocarcinoma or adenosquamous carcinoma histological subtype.\n* Planned for treatment with definitive chemo-radiation and brachytherapy. (X- ray,CT, CT-Ultrasound or MRI based).\n\nExclusion Criteria:\n\n* Neuroendocrine cancer of the cervix or other rare histology subtypes.\n* Patients with metastatic cervix cancer and not planned for radical doses of pelvic RT\u002Fbrachytherapy may be excluded.\n* Patients undergoing postoperative RT or RT for recurrent disease should be excluded.",{"count":189,"type":22},1000,"Gynecological cancer poses as significant public health issue, especially in Asian countries, where it is a leading cause of cancer-related deaths among women. Cervical cancer accounts for around 311,000 deaths annually, with over 85% occurring in low- and middle-income nations, primarily in Asia. Factors contributing to this burden include limited access to preventive care, inadequate screening, high rates of human papillomavirus infection, and cultural barriers that delay medical attention.\n\nFor patients with advanced cervical cancer, the standard treatment involves external beam radiation therapy along with chemotherapy followed by internal radiation, known as Brachytherapy. This technique uses unique set of devices placed internally at the tumor sitegiving localized radiation to the residual tumor tissue. While advanced brachytherapy techniques have been developed and practiced in Europe and American countries yielding excellent clinical outcomes, there is insufficient data on the use and results of such advanced brachytherapy techniques in Asian populations, leading to a lack of standardized practices.\n\nTo address these issues, the Asian Gynecological Brachytherapy Registry (ABGR) has been established as a collaborative platform for data collection and analysis on the use of Brachytherapy techniques. This registry aims to consolidate information from various healthcare settings across Asia, enhancing understanding of cervical cancer's epidemiology, evaluating treatment effectiveness, and identifying areas for improvement in patient care.",[192,193,194,195,196,197],"Stage IIIA Cervical Cancer FIGO 2018","Stage IIIB Cervical Cancer FIGO 2018","Stage IVA Cervical Cancer FIGO 2018","Stage IB Cervical Cancer FIGO 2018","Stage IIA Cervical Cancer FIGO 2018","Stage IIB Cervical Cancer FIGO 2018",[199,200],"Definitive chemo-radiation","Brachytherapy","2026-02-06",{"date":203,"type":42},"2026-02-09",{"date":102,"type":22},{"date":206,"type":22},"2028-05-20",{"name":48,"class":49},5,{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":86,"enrollmentInfo":217,"targetDuration":4,"studyType":23,"phases":218,"briefSummary":220,"conditions":221,"keywords":225,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":235,"locationsCount":236},"100624018","phase-2-study-to-assess-the-safety-and-effectiveness-of-novel-radiopharmaceutical-terbium-161-dotatate-in-metastatic-neuroendocrine-tumors-100624018","NCT07404176","Study to Assess the Safety and Effectiveness of Novel Radiopharmaceutical Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors","Terbium-161 DOTATATE in Metastatic Neuroendocrine Tumors: Assessment of Safety and Efficacy","TENET","Inclusion Criteria:\n\n* Male or female, age greater than 18 years\n* Histopathological diagnosis of well-differentiated GEP-NET\n* Positive Ga-68-DOTANOC PET\u002FCT, Krennings score \\>\u002F=3\n* Locally advanced\u002Finoperable disease or metastatic disease\n* Patient who have shown disease progression with Lu-177 DOTATATE PRRT\n* Karnofsky performance-status score of at least 60 or ECOG performance status \\\u003C\u002F=2\n* Life expectancy greater than 6 months\n\nExclusion Criteria:\n\n* Serum creatinine level of more than 1.6 mg\u002Fdl or a creatinine clearance of less than 50 ml\u002Fmin\n* Hemoglobin level of less than 8.0 g per deciliter\n* Red blood cell count less than 300,000\u002Fcubic millimeter\n* White cell count of less than 2000 per cubic millimeter\n* Platelet count of less than 75,000 per cubic millimetre\n* Total bilirubin level of more than 3 times the upper limit of the normal range\n* Serum albumin level \\> 3.0 g\u002Fdl\n* Pregnancy and Lactation\n* Patients with concurrent malignancies",{"count":5,"type":22},[219],"PHASE2","Gastro-enteropancreatic Neuro-endocrine tumors (GEP-NETs) are rare slow-growing cancers which commonly involve the abdominal organs like liver, stomach, intestines and pancreas. Their incidence has been documented to have increased over the last decade, thus resulting in treatment options being developed to treat these cancers. These cancers spread commonly to the liver, followed by lungs, bones and other sites. Depending on the extent of disease seen on scan, treatment is planned. Patients are advised Peptide Receptor Radionuclide Therapy (PRRT), which is the current standard of treatment for metastatic GEP-NETs. Radio-isotopes labeled to octreotide analogs bind to somatostatin receptors on surface of cancer cells and deliver radiation to the cancer cells when injected into the body. Lu-177 (Lutetium-177) is one such radioisotope which has been used for tagging to the octreotide and is known as Lu-177 DOTATATE PRRT, which is now routinely used in clinical practice. Terbium-161 is another radioisotope which can be labeled to octreotide and used for PRRT. It has advantages over Lu-177 such that it specifically reaches the tumor sites and does not affect the surrounding normal cells, due to its higher penetrating capacity and shorter range of travel. This will benefit patients as the effectiveness of PRRT will be higher with lesser side effects. However, the investigators can only do this by performing a study. Response to treatment can be evaluated by performing scans and side effects, if any can be studied by performing blood tests.",[222,223,224],"Neuroendocrine Neoplasms (Tumours)","Neuroendocrine Tumors","Metastatic Neuroendocrine Tumors",[226,227,228],"Terbium 161","metastatic NET","DOTATATE","2026-02-04",{"date":231,"type":42},"2026-02-11",{"date":233,"type":22},"2026-03-01",{"date":106,"type":22},{"name":48,"class":49},2,{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":243,"eligibilityCriteria":244,"healthyVolunteers":11,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":245,"targetDuration":18,"studyType":62,"phases":4,"briefSummary":247,"conditions":248,"keywords":252,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":257,"completionDateStruct":259,"leadSponsor":261,"locationsCount":236},"100615312","compliance-to-cervical-cancer-chemoradiation-guidelines-a-multicentric-implementation-audit-and-resource-assessment-initiative-of-national-cancer-grid-of-india-100615312","NCT07290972","Compliance to Cervical Cancer Chemoradiation Guidelines: A Multicentric Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","Compliance to Cervical Cancer Chemoradiation Guidelines: A Implementation Audit and Resource Assessment Initiative of National Cancer Grid of India","NCG-Compliance","The participating centers that agree to contribute data will include all registered cases over a 6 month period that have been diagnosed with histologically proven cervical cancer wherein either radical, adjuvant or palliative radiation with or without concurrent or systemic chemotherapy is planned.\n\nFurthermore any cases referred to the institution for brachytherapy alone will also be included.",{"count":246,"type":22},618,"This is a combination of retrospective and prospective observational study that will be performed across NCG and other participating centers to report compliance to chemoradiation for cervical cancer. This audit will include patients treated with standard of care treatment, in this case definitive or adjuvant radiation+\u002F- concurrent chemotherapy will be included. Patients recruited in various institutions in prospective clinical trials will not be included. The participating centersthat agree to contribute data will include all registered cases over a 6-month period that have been diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and\u002For concurrent chemotherapy. Centers that do not have retrospective data of the patients will contribute data of patients registered prospectively over 6 months. Furthermore, any cases referred to the institution for brachytherapy alone will also be included.\n\nAs a first step member institutions that participated in guideline development process or provide an agreement to guidelines adherence will be audited. The project will be submitted in institutional ethics committees with memorandum of understanding for anonymized data sharing.\n\nEach of the co-investigators listed from contributing centers will be directly responsible for collecting data contribution and accuracy of data submitted.\n\nThose centres which cannot or do not want to participate will be requested to provide data on only compliance outcomes to treatment for at least of 5 consecutively patients diagnosed with cervical cancer wherein treatment is planned with radical dose radiation and \u002For concurrent chemotherapy over a period of 6 months.",[249,250,143,251],"Cervical Cancer Screening","Gynecologic Cancers","Chemoradiotherapy",[95,96,97,253,254,251],"Treatment","Compliance","2026-02-03",{"date":229,"type":42},{"date":258,"type":42},"2021-02-01",{"date":260,"type":22},"2026-03-31",{"name":48,"class":49},{"id":263,"slug":264,"hasResults":11,"nctId":265,"briefTitle":266,"officialTitle":266,"acronym":4,"eligibilityCriteria":267,"healthyVolunteers":11,"sex":57,"minAge":4,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":274,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":78},"100606761","clinical-outcomes-and-quality-of-life-in-patients-with-locally-advanced-vulvovaginal-cancers-ambispective-registration-study-100606761","NCT07179757","Clinical Outcomes and Quality of Life in Patients With Locally Advanced Vulvovaginal Cancers: Ambispective Registration Study.","Inclusion Criteria:\n\n1. All patients diagnosed with vulvo- vaginal cancer.\n2. Patients treated with Radiation+\u002F- chemotherapy+\u002F-surgery from January 1, 2019- December 31, 2023.\n\nExclusion Criteria:\n\n1. Patients with Metastatic disease at the presentation.\n2. Incomplete information on the EMR.",{"count":269,"type":22},200,"The vaginal cancers are responsible for 2% of gynecological cancer while vulvar cancers account for 4 % of gynecological cancers. HPV 16 and 33 are most prevalent in vaginal cancers and account for more than half of cases HPV related vaginal cancer. However, adeqaute information is not there. Similarly, structured QOL data is not available for India. Therefore, in the proposed study we will like to systematically evaluate the patterns of relapse and disease outcomes in patients with vulvovaginal cancer treated with radiation (+\u002F- chemotherapy). The therapeutic research in vulvo-vaginal cancers has been relatively slow and such structured registration databases can allow analysis of large number of patients to report on acute and late effect of treatment outcomes using CTCAE and QOL (EORTC QLQ C-30 and VU-34) in rare cancers. We hope that we will get help in identifying thrust areas for future research including prospective interventional trials through this study.",[272],"Vulvo-vaginal Cancer",[144],{"date":229,"type":42},{"date":276,"type":42},"2021-10-30",{"date":278,"type":22},"2026-10-01",{"name":48,"class":49},{"id":281,"slug":282,"hasResults":11,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":286,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":288,"targetDuration":4,"studyType":23,"phases":290,"briefSummary":292,"conditions":293,"keywords":295,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":300,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":4},"100605593","phase-3-a-clinical-trial-to-assess-the-effectiveness-of-nrf2-activator-oral-sodium-copper--chlophyllin--in-locally-advanced-cervical-cancer-to-reduce-late-radiotherapy-toxicity-100605593","NCT07164534","A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.","A Phase III Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity. (CHOC-LATE Trial)","CHOC-LATE","Inclusion Criteria:\n\n* Female subjects aged 18 years or above with histologically proven locally advanced squamous cell or adenocarcinoma of the cervix\n* Subjects eligible for RT and planned for definitive RT +\u002F- chemotherapy with brachytherapy.\n* Subjects who exceed the dose constraints of:\n\n  * Rectum\u002Fsigmoid D 2cm³ EQD2 ³ by more than 70 Gy, or\n  * Bladder D 2cm³ EQD2 ³ more than 80 Gy\n* Subjects with adequate haematological, renal, hepatic and coagulation profiles and laboratory parameters within the following ranges:\n\n  * Haemoglobin: ≥ 8 g\u002Fdl\n  * ANC ≥ 1,500\u002Fmm\\^3\n  * Platelet count 100,000\u002Fmm\\^3\n  * Creatinine Clearance: ≥ 50 ml\u002Fmin (as per Cockcroft-Gault formula)\n  * Bilirubin: ≤ 2 x Upper limit of normal (ULN)\n  * AST and ALT: ≤ 1.5 x ULN\n* Subjects willing and able to comply with all study requirements, including treatment (e.g. able to swallow tablets), timing and\u002For nature of required assessments\n* Ability to understand and willingness to sign an informed consent document\n\nExclusion Criteria:\n\n* Subjects with known hypersensitivity or contraindication to the study drug or to any known component of the study drug formulation\n* Subjects with clinically significant decreased hematologic reserves, with major organ failure, severe electrolyte or metabolic abnormalities, any active infection or any other medical condition that may interfere with the ability to receive study treatment\n* HIV positive patients\n* Subjects with a history of blood dyscrasias\n* Subjects consuming any other concurrent investigational agents\n* Subjects with any other previous or current malignancy or RT that is likely to interfere with the protocol treatment, or any other condition which, according to the principal investigator, might make an individual unsuitable for this study\n* Subjects participating in any other clinical study within 90 days before enrolment in the study\n* Subjects on active anti-coagulant treatment",{"count":289,"type":22},316,[291],"PHASE3","Cervical cancer is the second most common cancer in Indian women, and most patients are diagnosed at advanced stages.\n\nThe standard treatment for these stages is concurrent chemoradiotherapy, but this can cause long-term side effects such as bladder inflammation, strictures, ulcers, and tissue damage, which negatively impact patients' quality of life.\n\nPrevious studies have shown that oral sodium-copper-chlorophyllin can help reduce radiation-related side effects in rectal, prostate, and cervical cancer patients. However, no study has compared side effects between patients receiving standard follow-up care and those taking sodium-copper-chlorophyllin during follow-up.\n\nWe hypothesize that the use of sodium-copper-chlorophyllin as a short-duration adjuvant is associated with reduced incidence of late grade 2 or higher gastrointestinal and genitourinary toxicities compared to patients receiving standard-of-care follow-up.",[294],"Uterine Cervical Neoplasm",[296,297,298,299],"cervix cancer","radiation-related adverse effects","radiation","sodium-copper-chlorophyllin",{"date":229,"type":42},{"date":302,"type":22},"2026-03",{"date":304,"type":22},"2030-09",{"name":48,"class":49},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":312,"eligibilityCriteria":313,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":314,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":316,"conditions":317,"keywords":319,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":322,"startDateStruct":323,"completionDateStruct":325,"leadSponsor":327,"locationsCount":78},"100577887","systemic-and-tumor-immune-response-during-pelvic-chemoradiation-andor-brachytherapy-for-cervical-cancer-100577887","NCT06804135","Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and\u002For Brachytherapy for Cervical Cancer","Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and\u002For Brachytherapy for Cervical Cancer (STIRR Cervix Study)","STIRR","Inclusion Criteria:\n\n* Common Inclusion Criteria:\n\n  1. Age 18 years and above.\n  2. Ability to tolerate full course of pelvic radiotherapy+\u002F- chemotherapy +\u002F- brachytherapy.\n  3. Ability to understand and willingness to sign an informed consent document.\n  4. Should be willing to undergo extra biopsies and blood samples collection for translational research study.\n\nCohort A:\n\n1. Patients diagnosed with LACC Stage IB2 - IIIC1, as per FIGO 2018 Classification for Radical Cohort.\n2. Stage IIIB-IVA where palliative RT is indicated for palliative cohort.\n3. No previous irradiation to the pelvis or chemo therapy.\n\nCohort B:\n\n1. Patients diagnosed with LACC Stage IIIC2, as per FIGO 2018 Classification.\n2. No previous irradiation to the pelvis or chemotherapy.\n\nCohort C:\n\n1. Patients diagnosed with gynecological cancer and presenting with need of infield radiation.\n2. Planned for reirradiation.\n\nExclusion Criteria:\n\n1. Severe medical condition impairing complete treatment delivery.\n2. Patients with immunocompromised states or active infection.\n3. Patients on immunosuppressive drugs for other medical conditions.\n4. Patients who will receive immune checkpoint inhibition (ICI) therapy.",{"count":315,"type":22},110,"Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression. Thus the investigators hypothesize that pelvic and\u002For para-aortic radiotherapy for cervical cancer affects local tumor immunity as well as systemic immune response that may be instrumental for long term cancer cure. The goal of this observational study is to understand the effect of various radiotherapy dose per fraction, total dose and field volumes of radiation on systemic and tumor immune response in cervical cancer. The outcome of the study would be useful in improving the quality of radiation treatment and in reducing disease recurrence and improving survival in patients with cervical cancer.",[318],"Cervical Carcinoma",[91,320,144,321],"Immune System","PD-L1 Expression",{"date":229,"type":42},{"date":324,"type":42},"2025-10-25",{"date":326,"type":22},"2030-01-30",{"name":48,"class":49},{"id":329,"slug":330,"hasResults":11,"nctId":331,"briefTitle":332,"officialTitle":333,"acronym":334,"eligibilityCriteria":335,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":336,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":338,"conditions":339,"keywords":342,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":78},"100619254","fapi-pet-in-pancreatic-ductal-adenocarcinoma-100619254","NCT07342231","FAPi PET in Pancreatic Ductal Adenocarcinoma","FAP-1 Study: FAPi PET in Pancreatic Ductal Adenocarcinoma: A Prospective, Exploratory Study","FAP-1","Inclusion Criteria:\n\n* Any gender with age more than 18 years\n* Patients with biopsy-proven pancreatic ductal adenocarcinoma\n* Patient willing to participate in study\n\nExclusion Criteria:\n\n* Patient with concurrent malignancy\n* Pregnancy and lactation",{"count":337,"type":22},60,"Pancreatic adenocarcinoma commonly referred to as pancreatic cancer is a cancer which is known to involve the pancreas and the surrounding structures like blood vessels, which makes it an aggressive cancer. Treatment of the cancer is decided by how much the disease has spread. It has been understood from recent studies that there are some components of the tumor which are not detected by standard CT scan. The tissue in the tumor microenvironment leads to further spread of tumor. The tissue which is seen near the tumor has many attachments on the surface which are currently being studied. One of the most common attachments is Fibroblast activation protein (FAP), which is seen on the surface of tumor tissue. A radioactive tracer Gallium-68 is attached to a small protein known as 'peptide' named 'FAP inhibitor (FAPi)' which shall bind to FAP. Then a PET scan will be performed which shall help in understanding how much of the tissue is seen on the scan in addition to the pancreatic tumor. The investigators shall assess whether the radiotracer (Gallium-68 labeled FAPi) binds to other sites like liver or other organs where the cancer is likely to spread. From the study, the investigators shall study whether the new scanning technique is beneficial as compared to the standard CT scanning. Hence, the investigators would perform Gallium-68-labeled FAPi PET scan in addition to the standard CT scan and compare the results.",[340,341],"Pancreatic Cancer","Adenocarcinoma Pancreas",[343,344,345],"Fibroblast activation protein","PETCT","FAPi","2026-01-07",{"date":348,"type":42},"2026-01-15",{"date":350,"type":42},"2025-01-04",{"date":352,"type":22},"2027-01-01",{"name":48,"class":49},{"id":355,"slug":356,"hasResults":11,"nctId":357,"briefTitle":358,"officialTitle":359,"acronym":360,"eligibilityCriteria":361,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":4,"enrollmentInfo":362,"targetDuration":4,"studyType":23,"phases":364,"briefSummary":365,"conditions":366,"keywords":370,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":376,"lastUpdatePostDateStruct":377,"startDateStruct":379,"completionDateStruct":381,"leadSponsor":383,"locationsCount":236},"100607216","phase-3-prrt-versus-prrt-plus-chemotherapy-in-gep-net-precedent-trial-100607216","NCT07185672","PRRT Versus PRRT Plus Chemotherapy in GEP NET (PReCedeNT Trial)","PReCedeNT Trial: Phase III Randomised Controlled Open Label Trial of Lutetium 177 PRRT Plus Chemotherapy Versus PRRT Aalone in FDG Avid Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors","PReCedeNT","Inclusion Criteria:\n\n* Male or female, age greater than 18 years\n* Histopathological diagnosis of GEP-NET, necessarily satisfying all the the criteria below\n* Well differentiated G2 (Ki67 : ≥3-20%) OR G3 (ki67- greater than 20-55%), OR\n* Well-differentiated G1 (\\\u003C3%) with disease progression in last 6 months\n* Positive Ga-68-DOTANOC PET\u002FCT, Krennings score \\>\u002F=3\n* Positive FDG PET imaging, grade 3 or 4 uptake\n* Locally advanced\u002Finoperable disease or metastatic disease\n* Karnofsky performance-status score of at least 60 or ECOG performance status \\\u003C\u002F= 2\n* Life expectancy greater than 6 months\n\nExclusion Criteria:\n\n* Serum creatinine level of more than 1.6 mg\u002Fdl or a creatinine clearance of less than 50 ml\u002Fmin\n* Hemoglobin level of less than 8.0 g per deciliter\n* Red blood cell count noty less than 300,000\u002Fcubic millimeter White cell count of less than 2000 per cubic millimeter\n* Platelet count of less than 75,000 per cubic millimetre\n* Total bilirubin level of more than 3 times the upper limit of the normal range\n* Serum albumin level \\\u003C 3.0 g\u002Fdl\n* Treatment with more than 30 mg of octreotide LAR within 4 weeks before randomisation.\n* Peptide receptor radionuclide therapy at any time before randomisation\n* Pregnancy and Lactation\n* Patients with concurrent malignancies",{"count":363,"type":22},162,[291],"Neuroendocrine tumours (NETs), better defined as neoplasms (NENs), are a heterogeneous group of neoplasms that range from well-differentiated tumours to more aggressive carcinomas. Peptide receptor radionuclide therapy (PRRT) with Lutetium-177 DOTATATE is the established standard of care for patients with well-differentiated metastatic or locally advanced GEP-NETs. It has demonstrated a significant improvement in outcomes compared to Octreotide LAR, both as a first-line and second-line treatment approach, following the results of NETTER-1 and NETTER-2 trials, respectively. ENETS guidelines recommend the use of Ga-68 labeled DOTANOC\u002FTOC\u002FTATAE imaging only for WHO Grade 1 NET whereas FDG PET is the preferred modality for WHO Grade 3 NEN and NEC. For Grade 2 tumors (Mib index ranging from 3-20%), there are no strong recommendations for the addition of FDG PETCT in existing diagnostic algorithm. FDG PET positivity has been shown to be an independent predictor of shorter progression-free and overall survival in NET patients undergoing peptide receptor radionuclide therapy (PRRT). (8) Consequently, it is imperative to address FDG-avid tumors by integrating PRRT and chemotherapy. There are no strong recommendations for the grade wise management of GEP-NETs particularly grade 2 \\& 3. Although recently published NETTER 2 trial substantiated the role of PRRT as a first line treatment for advanced grade GEP-NETs, still there is lack of evidence supporting the addition of chemotherapy in management of GEP-NETs. Given the absence of a prospective study to establish this treatment regimen, we designed a Phase 3 Randomized Controlled Trial to evaluate the combination of PRRT and CAPE-TEM-based chemotherapy in patients with FDG-positive metastatic well-differentiated NETs.",[367,368,369],"Neuroendocrine Neoplasia's (NENs)","Neuroendocrine Tumor GEP Grade 1-3","Neuroendocrine Gastroenteropancreatic Tumour",[371,372,373,374,375],"Peptide Receptor Radionuclide Therapy","Lu-177 DOTATATE","PRRT","Neuroendocrine tumor","Capecitabine-Temozolamide","2025-09-17",{"date":378,"type":42},"2025-09-22",{"date":380,"type":42},"2019-08-07",{"date":382,"type":22},"2027-08-07",{"name":48,"class":49},{"id":385,"slug":386,"hasResults":11,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":390,"eligibilityCriteria":391,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":392,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":401,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":411,"completionDateStruct":413,"leadSponsor":415,"locationsCount":78},"100460608","phase-2-local-consolidative-radiation-therapy-plus-tki-versus-tki-alone-in-driver-mutated-om-nsclc-100460608","NCT05277844","Local Consolidative Radiation Therapy Plus TKI Versus TKI Alone in Driver Mutated OM-NSCLC","A Phase II Randomized Controlled Trial of TKI Alone Versus TKI and Local Consolidative Radiation Therapy in Oncogene Driver Mutated Oligo Metastatic Non Small Cell Lung Cancer Patients","TARGET-01","Inclusion Criteria:\n\n1. Patients with pathologically proven diagnosis of NSCLC\n2. Patients with positive oncogene driver mutation (EGFR or ALK\u002FROS)\n3. Patients who have received at least 2-4 months of TKI therapy without progression\n4. Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than 3 metastatic lesions in one organ will be eligible and 4 or more metastatic lesions in one organ will be ineligible)\n5. Patients suitable for local consolidative therapy\n6. Adequate end-organ function CBC\u002Fdifferential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows:\n\n   * Absolute neutrophil count (ANC) ≥ 500 cells\u002Fmm3;\n   * Platelets ≥ 50,000 cells\u002Fmm3;\n   * Hemoglobin ≥ 8.0 g\u002Fdl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable);\n7. Patients with ECOG performance status of 0-2\n8. Age \\> 18 years\n9. For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration\n\nExclusion Criteria:\n\n1. Patients with progressive disease after 2-3 months of initial TKI therapy\n2. Patients with negative oncogene driver mutations (EGFR\u002FALK\u002FROS)\n3. Patients not suitable for local consolidative radiation therapy\n4. Patients who are not suitable for further continuation of TKI therapy due to toxicity\n5. Severe, active co-morbidity defined as follows:\n\n   * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months;\n   * Transmural myocardial infarction within the last 6 months;\n   * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;\n6. Patients with prior history of radiation therapy to thorax\n7. Patients with second malignancy (Synchronous or Metachronous)\n8. Pregnancy","99 Years",{"count":394,"type":22},106,[219],"A Phase II randomized controlled trial of TKI Alone versus TKI and Local Consolidative Radiation Therapy in oncogene driver mutated oligo metastatic Non-small cell lung cancer patients.",[398,399,400],"Oligometastatic Disease","Non-small Cell Lung Cancer","Driver Mutation",[402,403,404,405,406,407],"Oligometastatic NSCLC","Driver mutation","TKI","Local consolidative therapy","SABR","Oligometastases","2025-09-03",{"date":410,"type":42},"2025-09-10",{"date":412,"type":42},"2019-11-11",{"date":414,"type":22},"2027-11-11",{"name":48,"class":49},{"id":417,"slug":418,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":422,"eligibilityCriteria":423,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":392,"enrollmentInfo":424,"targetDuration":4,"studyType":23,"phases":426,"briefSummary":427,"conditions":428,"keywords":430,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":435,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":78},"100460624","phase-3-standard-maintenance-therapy-smt-vs-local-consolidative-radiation-therapy-and-smt-in-om-nsclc-100460624","NCT05278052","Standard Maintenance Therapy (SMT) vs Local Consolidative Radiation Therapy and SMT in OM-NSCLC","Standard Maintenance Therapy Versus Local Consolidative Radiation Therapy and Standard Maintenance Therapy in 1-5 Sites of Oligometastatic Non-small Cell Lung Cancer (NSCLC): A Phase III Randomized Controlled Trial","TARGET-02","Inclusion Criteria:\n\n1. Age \\> 18 years\n2. Patients with ECOG performance status of 0-2\n3. Patients with pathologically proven diagnosis of NSCLC\n4. Patients with 1-5 sites of metastatic disease not including the primary tumor and regional nodes (less than or equal to 3 metastatic lesions in one organ will be eligible and 4 or more metastatic lesions in one organ will be ineligible)\n5. Patients who have received standard duration of systemic therapy (4 - 6 cycles) without progression of the disease\n6. Patients suitable for definitive therapy to the primary disease\n7. All the Oligometastases lesions should be radiologically visible and suitable for ablative doses of radiation in accordance with the dose fractionation regimens specified in the protocol.\n8. Patients who have received ablative radiation therapy or surgery or RFA for metastatic sites at presentation or during systemic therapy will be eligible provided the total number of oligometastatic sites at the time of study entry (treated site included) is less than or equal to five.\n9. Patients who have received palliative RT for symptomatic bony metastases or RFA will also be eligible provided the treated site is under control on imaging. If not controlled, could be eligible for study if further ablative doses of radiation can be delivered according to the treating physician.\n10. Patients who underwent surgical decompression, or stabilization followed by palliative radiation therapy for bony metastases will be eligible in the study provided the treated site is under control on imaging and patient has less than 5 sites of metastases at the time of study entry.\n11. Adequate end organ function CBC\u002Fdifferential obtained within 15 days prior to registration on study, with adequate bone marrow function defined as follows:\n\n    * Absolute neutrophil count (ANC) ≥ 500 cells\u002Fmm3;\n    * Platelets ≥ 50,000 cells\u002Fmm3;\n    * Hemoglobin ≥ 8.0 g\u002Fdl (Use of transfusion or other intervention to achieve Hgb ≥ 8.0 g\u002Fdl is acceptable);\n12. For females of child-bearing potential, negative serum or urine pregnancy test within 14 days prior to study registration;\n13. Patients willing for written informed consent and must be willing to comply with the specified follow up schedule\n\nExclusion Criteria:\n\n1. Patients with progressive disease after initial standard systemic therapy\n2. Patients with oncogene driver mutations\n3. Patients with more than 5 sites of oligo metastases\n4. Patients with metastatic lesion size of more than 5 cm\n5. Patients with more than three metastatic lesion in one organ\n6. Patients not suitable for definitive radiation therapy to primary disease\n7. Patients not suitable for ablative radiation therapy to metastatic sites\n8. Patients with malignant peritoneal disease\n9. Patients with malignant pleural effusion\n10. Leptomeningeal disease\n11. Brain metastases in the brain stem\n12. Clinical or radiological evidence of spinal cord compression or metastases within 2 mm of spinal cord on MRI\n13. Severe, active co-morbidity defined as follows:\n\n    * Unstable angina and\u002For congestive heart failure requiring hospitalization within the last 6 months;\n    * Transmural myocardial infarction within the last 6 months;\n    * Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;\n14. Patients with prior history of radiation therapy to thorax\n15. Patients with previous history of malignancy within last 3 years from the date of diagnosis\n16. Pregnancy",{"count":425,"type":22},190,[291],"Standard Maintenance Therapy versus Local Consolidative Radiation Therapy and standard maintenance therapy in 1-5 sites of OligoMetastatic Non-small cell lung cancer (NSCLC): A Phase III Randomized Controlled Trial",[398,429],"Metastatic Non Small Cell Lung Cancer",[431,432,433,434,406],"Local Consolidative Radiation Therapy","Oligometastatic disease","NSCLC","Maintenance therapy",{"date":410,"type":42},{"date":437,"type":42},"2020-04-20",{"date":439,"type":22},"2028-04-20",{"name":48,"class":49},{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":392,"enrollmentInfo":448,"targetDuration":4,"studyType":23,"phases":449,"briefSummary":450,"conditions":451,"keywords":454,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":78},"100457465","phase-3-observation-or-upfront-cranial-rt-in-oncogene-mutated-nsclc-with-asymptomatic-bm-a-phase-iii-rct-100457465","NCT05236946","Observation or Upfront Cranial RT in Oncogene Mutated NSCLC With Asymptomatic BM: A Phase III RCT","Observation or Upfront Cranial RT in Oncogene Driver Mutated NSCLC With Asymptomatic Brain Metastases: A Phase III Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients with ECOG performance status of 0-2\n3. Patients with pathologically proven diagnosis of NSCLC\n4. Patients with positive oncogene mutation status (EGFR\u002FALK)\n5. Patients with radiologically confirmed parenchymal brain metastases\n6. Patients with asymptomatic Synchronous or Metachronous brain metastases\n7. Patients willing for written informed consent and must be willing to comply with the specified follow-up schedule\n\nExclusion Criteria:\n\n1. Patients with CSF dissemination only without any parenchymal brain metastases\n2. Patients with brain metastases in the brain stem\n3. Patients with prior history of radiation therapy to the brain\n4. Patient not suitable for TKI therapy as per the medical oncologist\n5. Pregnant or lactating females",{"count":425,"type":22},[291],"Tyrosine Kinase Inhibitors (TKIs) especially higher generation TKI have higher CNS penetration rates and have shown favorable response rates in brain metastases. Brain radiotherapy\u002Fsurgery is the standard treatment in brain metastases especially symptomatic metastases, however, the role of local treatment especially in driver mutation-positive non-small cell lung cancer with asymptomatic brain metastases is being questioned given their potential side effects. No randomized trial has shown the superiority of early vs delayed cranial RT in asymptomatic BM of driver mutated NSCLC.",[452,453],"Asymptomatic Brain Metastases","Driver Mutation Positive Non-small Cell Lung Cancer",[455,456,457,458,459],"Asymptomatic brain metastases","EGFR mutation","Whole brain radiotherapy","Stereotactic radiosurgery","ALK rearrangement",{"date":410,"type":42},{"date":462,"type":42},"2020-11-10",{"date":464,"type":22},"2026-12",{"name":48,"class":49},{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":471,"eligibilityCriteria":472,"healthyVolunteers":11,"sex":57,"minAge":58,"maxAge":4,"enrollmentInfo":473,"targetDuration":4,"studyType":62,"phases":4,"briefSummary":475,"conditions":476,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":478,"startDateStruct":479,"completionDateStruct":481,"leadSponsor":483,"locationsCount":78},"100346956","a-prospective-evaluation-of-the-peri-operative-hypoxia-in-breast-cancer-100346956","NCT03797482","A Prospective Evaluation of the Peri-operative Hypoxia in Breast Cancer","Hypoxia","Inclusion Criteria:\n\n1. Clinically diagnosis of breast cancer (by FNAC or Biopsy)\n2. Not received any chemotherapy or surgical intervention except core biopsy.\n3. Planed for Breast cancer surgery\n4. Willing to give consent for the study\n\nExclusion Criteria:\n\n1. Clinically diagnosis of Metastatic breast cancer\n2. Received any anticancer therapy",{"count":474,"type":22},500,"To understand the effects induced by acute hypoxia that sets in during surgery in breast cancer. To study this, clinical samples (Tumor biopsies) will be obtained during the surgery after partial devascularisation (sample B) and stored for future genomic and proteonomic evaluations.",[477],"Breast Cancer Female",{"date":410,"type":42},{"date":480,"type":42},"2017-11-27",{"date":482,"type":22},"2025-11-30",{"name":48,"class":49},{"id":485,"slug":486,"hasResults":11,"nctId":487,"briefTitle":488,"officialTitle":489,"acronym":490,"eligibilityCriteria":491,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":492,"enrollmentInfo":493,"targetDuration":4,"studyType":23,"phases":495,"briefSummary":496,"conditions":497,"keywords":505,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":513,"lastUpdatePostDateStruct":514,"startDateStruct":516,"completionDateStruct":518,"leadSponsor":520,"locationsCount":521},"100498763","sentinel-node-biopsy-versus-limited-elective-neck-dissection-in-early-cancers-of-oral-cavity-node-negative-100498763","NCT05774483","Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative","Sentinel Node Biopsy Versus Limited Elective Neck Dissection in Early Cancers of Oral Cavity NoDe Negative (SECOND N0): Non-inferiority Phase III Trial","SECOND N0","Inclusion Criteria:\n\n1. Age \\>18 years of age\n2. Biopsy-proven invasive squamous cell carcinoma involving the site tongue and buccal mucosa\n3. T1 and T2 lesions as per AJCC TNM 8 edition\n4. Clinicoradiologically node negative\n5. Amenable to per oral excision\n6. Treatment naïve\n7. No other site of malignancy\n\nExclusion Criteria:\n\n1. Previous surgery in the head and neck region,\n2. Upper alveolar or palatal lesions\n3. Large heterogeneous leukoplakia or other premalignant lesions\n4. Previous malignancy in the head and neck region\n5. Patients requiring the free flap reconstruction","80 Years",{"count":494,"type":22},508,[25],"The goal of this clinical trial is to compare the survival outcomes, morbidity and cost-effectiveness of sentinel node biopsy versus limited elective neck dissection in node-negative early oral cancers.\n\nThe main questions it aims to answer are:\n\n* Survival outcomes\n* Morbidity outcomes\n* Cost-effectiveness\n\nParticipants will either undergo sentinel node biopsy followed by completion neck dissection if sentinel node is reported to be metastatic (SNB) or limited elective neck dissection where level IIb will be cleared only if level IIa is metastatic (limited END). The study will compare the outcomes in the two cohorts.",[498,499,500,501,502,503,504],"Mouth Neoplasms","Oral Cancers","Oral Squamous Cell Carcinoma (OSCC)","Oral Squamous Cell Carcinomas","Sentinel Lymph Node Biopsy","Sentinel Lymph Node Biopsy (SLNB)","Sentinel Lymph Node",[506,507,508,509,510,511,512],"mouth neoplasms","neck dissection","sentinel lymph node biopsy","survival","morbidity","oral cancers","oral squamous cell carcinoma","2025-07-14",{"date":515,"type":42},"2025-07-17",{"date":517,"type":42},"2025-04-16",{"date":519,"type":22},"2034-04",{"name":48,"class":49},3,{"id":523,"slug":524,"hasResults":11,"nctId":525,"briefTitle":526,"officialTitle":527,"acronym":528,"eligibilityCriteria":529,"healthyVolunteers":11,"sex":17,"minAge":58,"maxAge":530,"enrollmentInfo":531,"targetDuration":4,"studyType":23,"phases":533,"briefSummary":534,"conditions":535,"keywords":537,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":546,"completionDateStruct":548,"leadSponsor":550,"locationsCount":78},"100283076","radiation-dose-optimization-in-diffuse-large-b--cell-lymphoma-100283076","NCT02964858","Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma.","Radiation Dose Optimization in Diffuse Large B- Cell Lymphoma (DOBL) - A Randomised Phase III Non- Inferiority Trial.","DOBL","Inclusion Criteria:\n\n* Histological Diagnosis of NHL- DLBCL.\n* Eligible for RT after R-CHOP.\n* ECOG 0-3.\n* 18 - 65 years.\n* Stage I-IV.\n* Patients should receive at least 4 cycles of R-CHOP chemotherapy.\n* Patients with all extranodal disease except the ones mentioned in the exclusion criteria.\n* Able to understand and willing to provide informed consent for participation in the trial.\n\nExclusion Criteria:\n\n* HIV positive status.\n* Relapse or progression of disease during chemotherapy.\n* Prior history of chemotherapy\n* Prior history of radiotherapy.\n* Systemic lymphomas with CNS involvement.\n* Primary extranodal Testicular Lymphomas.\n* Primary extranodal central nervous system (CNS) Lymphomas.\n* Primary extranodal Stomach DLBCL\n* Primary extranodal Intestinal DLBCL\n* Patients \\>3 extranodal sites","65 Years",{"count":532,"type":22},840,[25],"The purpose of this study is to compare standard dose radiation of 45 Gray(Gy) in 25 fractions in Non Hodgkin's Lymphoma- Diffuse Large B cell Lymphoma (NHL-DLBCL) to that of 36 Gy in 20 fractions.\n\nThe role of radiation in NHL-DLBCL has been addressed in large cooperative trials showing improvement in overall survival and progression free survival with combined modality treatment. The doses of radiation used in these trials are heterogeneous ranging from 30-55 Gray(Gy). There is uncertainty about the optimal dose of radiation needed in aggressive lymphomas. A dose response phenomenon is known in Non- Hodgkin's Lymphoma. Late effects of higher dose radiation in the form of higher risk of stroke, myocardial infarction, thyroid abnormalities and secondary breast cancer are being increasingly identified. Hence it is essential to optimize the dose of radiotherapy for lower toxicity without compromising on efficacy.",[536],"NonHodgkin Lymphoma",[538,539,540,541,542],"Radiation Dose","Optimization","NHL","DLBCL","R-CHOP","2025-04-08",{"date":545,"type":42},"2025-04-11",{"date":547,"type":4},"2016-11",{"date":549,"type":22},"2027-11",{"name":48,"class":49},""]